艾普拉唑序贯治疗消化性溃疡的临床研究及对血清胃泌素与胃泌素基因表达的影响  

Clinical Research of Ilaprazole Sequential in treatment of Peptic Ulcer and the Effects on Serum Gastrin and Gastrin Gene Expression

作　　者：吴大威 杨玉双 崔青志 王立维 张清 王静 刘立奇 WU Dawei;YANG Yushuang;CUI Qingzhi(The 203rd Hospital of PLA,Heilongjiang Qigihar 161000,China)

机构地区：[1]中国人民解放军第203医院消化呼吸科,黑龙江齐齐哈尔161000

出　　处：《河北医学》2018年第5期791-794,共4页Hebei Medicine

基　　金：黑龙江省自然基金项目;(编号:D201178)

摘　　要：目的:研究艾普拉唑序贯治疗消化性溃疡的临床研究及对血清胃泌素与胃泌素基因表达的影响。方法:收集2015年3月至2016年3月我院的80例消化性溃疡患者,按抽签法分为实验组和对照组,每组各40例。对照组采用常规治疗,口服奥美拉唑、克拉霉素胶囊、呋喃唑酮片。实验组采用艾普拉唑序贯治疗,口服艾普拉唑肠溶片、克拉霉素胶囊、呋喃唑酮片。对比两组症状缓解、愈合时间、愈合率、HP根除时间、HP根除率,血清胃泌素与胃泌素基因表达,不良反应发生率,治疗疗效。结果:实验组症状缓解、愈合时间、愈合率、HP根除时间、HP根除率均显著优于对照组[92.50%(37/40)vs75.00%(30/40),(6.93±1.35)周vs(3.29±0.74)周,92.50%(37/40)vs75.00%(30/40),(7.49±1.67)d vs(10.86±2.45)d,95.00%(38/40)vs75.00%(30/40)](P<0.05);胃泌素、胃泌素基因表达均显著低于对照组[(24.57±6.04)pmo L/L vs(28.09±6.37)pmo L/L,(0.13±0.02)pmo L/L vs(0.25±0.05)pmo L/L](P<0.05);不良反应总发生率显著低于对照组[10.00%(4/40)vs42.50%(17/40)](P<0.05);总有效率显著高于对照组[95.00%(38/40)vs70.00%(28/40)](P<0.05)。结论:艾普拉唑序贯治疗消化性溃疡的临床疗效显著,能够减轻溃疡局部炎症反应,减少胃酸分泌,降低血清胃泌素水平与胃泌素基因表达,可显著提高治疗疗效和用药安全性。Objective： To study clinical research of Ilaprazole sequential in treatment of peptic ulcer and the effects on serum gastrin and gastrin gene expression. Methods： 80 patients of peptic ulcer who received therapy from March 2015 to March 2016 in our hospital were selected as research objects. According to the draw method divided into control group and experimental group,all the 40 cases. The control group was treated with routine treatment,oral omeprazole,Clarithromycin Capsules,Furazolidone Tablets. while the observation group was treated with Ilaprazole sequential,Ilaprazole Enteric-coated Tablets,Clarithromycin Capsules,Furazolidone Tablets oral. Then symptom relief,healing time,healing rate,HP eradication time,HP eradication rate,serum gastrin and gastrin gene expression,adverse reaction rate,treatment effect of two groups were compared. Results： The symptom relief,healing time,healing rate,HP eradication time and HP eradication rate in the experimental group were significantly lower than those in the control group[92.50%（ 37/40） vs75.00%（ 30/40）,（ 6.93±1.35） week vs（ 3.29 ± 0.74） week,92.50%（ 37/40） vs75.00%（ 30/40）,（ 7.49 ± 1.67） d vs（ 10.86±2.45） d,95.00%（ 38/40） vs75.00%（ 30/40） ]（ P〈0.05）; The gastrin and gastrin gene expressions were significantly lower than those in the control group [（ 24.57±6.04） pmo L/L vs（ 28.09±6.37） pmol/L,（ 0.13±0.02） pmol/L vs（ 0.25 ± 0.05） pmo L/L]（ P〈0.05）; The total incidence of adverse reactions was significantly lower than that of the control group[10.00%（ 4/40） vs42.50%（ 17/40） ]（ P〈0.05）; The total effective rate was significantly higher than that of the control group[95.00%（ 38/40） vs70.00%（ 28/40） ]（ P〈0.05）.Conclusion： Ilaprazole sequential is well for peptic ulcer,which can reduce the local inflammatory reaction of ulcer,reduce gastric acid secretion,reduce serum gastrin level and gastrin gene expression,and can significantly improve therapeutic efficacy and

关 键 词：艾普拉唑序贯 消化性溃疡 胃泌素基因 

分 类 号：R573.1[医药卫生—消化系统]